期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性淋巴细胞白血病的治疗 被引量：4

Treatments of chronic lymphocytic leukemia
暂未订购
导出
摘要 在过去的20年里,随着对慢性淋巴细胞白血病(CLL)生物学机制的不断认识,CLL的治疗策略取得了诸多进展,其疗效得到进一步的提高。为更好了解CLL治疗最新发展动态,为CLL患者提供规范化和个体化治疗,现对目前CLL治疗的新进展进行综述。 In the past two decades,with the increasing exploration in the biological mechanisms of chronic lymphocytic leukemia （CLL）,a lot of progresses have been made in the investigation of new therapeutic strategies,resulting in great improvement in the therapeutic efficacy of CLL.In order to keep abreast of the latest developments in the treatment of CLL and provide standard and individualized treatment forthe patients with CLL,major advances in the therapeutics of CLL were reviewed.
作者 崔久嵬
机构地区 吉林大学第一医院肿瘤中心
出处 《临床荟萃》 CAS 2014年第10期1119-1125,共7页 Clinical Focus
关键词 白血病 淋巴细胞 慢性 B细胞 分子靶向治疗 leukemia,lymphocyte,chronicity,B-cell molecular targeted therapy
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献45

  • 1NCCN.guideline version 1.2014 CLL/SLL[S].www.lshospital,zj.cn/S.2011-09-14.
  • 2Knauf WU,Lissitchkov T,Aldaoud A,et al.Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia:updated results of a randomized phase Ⅲ trial[J].Br J Haematol,2012,159(1):67-77.
  • 3Kataeva E,Golenkov A,Triphonova E,et al.Efficacy of bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia[J].Blood,2013,122(21):Abstract 5312.
  • 4Carson DA,Wasson DB,Kaye J,et al.Deoxycytidine kinasemediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210leukemia in vivo[J].Proc Natl Acad Sci U S A,1980,77 (11):6865-6869.
  • 5Mulligan SP,Karlsson K,Stromberg M,et al.Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia[J].Leuk Lymphoma,2014 Apr 16.[Epub ahead of print].
  • 6Brogden RN,Sorkin EM.Pentostatin.A review of its pharmacodynamic and pharmacokinetic properties,and therapeutic potential in lymphoproliferative disorders[J].Drugs,1993,46(4):652-677.
  • 7郑文,傅志英,涂梅峰,林宁晶,刘卫平,谢彦,王小沛,宋玉琴,平凌燕,应志涛,邓丽娟,张晨,朱军.重组抗CD52单克隆抗体治疗复发难治慢性淋巴细胞白血病和外周T细胞淋巴瘤的Ⅰ期临床研究[J].中国新药杂志,2012,21(17):2041-2046. 被引量：2
  • 8Coiffier B,Lepretre S,Pedersen LM,et al.Safety and efficacy of ofatumumab,a fully human monoclonal anti-CD20 antibody,in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:a phase 1-2 study[J].Blood,2008,111 (3):1094-1100.
  • 9Gravanis I,Ersboll J,Skovlund E,et al.The European Medicines Agency review of ofatumumab (Arzerra) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab:summary of the scientific assessment of the European medicines agency committee for medicinal products for human use[J].Oncologist,2010,15(12):1335-1343.
  • 10Goede V,Fischer K,Busch R,et al.Head-to-head comparison of obinutuzumab (GA101) plus Chlorambucil (clb) versus rituximab plus clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities):final stage 2 results of the CLL11 trial[J].Blood,2013,122 (21):Abstract 6.

二级参考文献46

  • 1Sthoeger ZM, Sthoeger D, Shtalrid M,et al. Mechanism of autoimmune hemolytic anemia in chronic lymphocytic leuke mia[J]. Am J Hematol, 1993,43(4) :259-264.
  • 2Centola M, Lin K, Sutton C, et al. Production of antieryth rocyte antibodies by leukemic and nonleukemic B cells in chro nic lymphocytic leukemia patients [J]. Leuk Lymphoma 1996, 20(5-6) :465-469.
  • 3Kipps TJ. Immunobiology of chronic lymphocytic leukemia [J]. Curr Opin Hematol, 2003, 10(4) :312-318.
  • 4Hall AM, Vickers MA, McLeod E, et al. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells[J]. Blood, 2005, 105(5) :2007-2015.
  • 5D'Arena G, Cascavilla N. Chronic lymphocytic leukemia-asso- ciated autoimmune hemolytic anemia[J]. Leuk Lymphoma, 2007, 48(6):1072-1080.
  • 6Galletti J, Caones C, Morande P, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia [J]. J Immunol, 2008,181(5) :3674-3683.
  • 7Duek A, Shvidel L, Braester A,et al. Clinical and immuno- logic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders[J]. Isr Med Assoc J, 2006, 8 (12) :828-831.
  • 8Piccirillo CA, Thornton AM. Cornerstone of peripheral tol erance: naturally occurring CD4+ CD25+ regulatory T cells [J]. Trends Immunol, 2004, 25(7) :374-380.
  • 9Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor im munity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity[J]. J Immunol, 1999, 163(10):5211-5218.
  • 10Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic selftolerance maintained by CD25 + CD4 + naturally anergie andsuppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state [J]. Int Immunol, 1998,10(12) :1969-1980.

共引文献11

同被引文献18

引证文献4

二级引证文献20

临床荟萃
2014年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部